Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 24, 2013

Primary Completion Date

July 29, 2021

Study Completion Date

October 30, 2024

Conditions
GlioblastomaRecurrent Glioblastoma
Interventions
DRUG

Adavosertib

Given PO

RADIATION

Radiation Therapy

Undergo radiation therapy

DRUG

Temozolomide

Given PO

Trial Locations (12)

10065

Memorial Sloan Kettering Cancer Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

19104

University of Pennsylvania/Abramson Cancer Center, Philadelphia

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

35233

University of Alabama at Birmingham Cancer Center, Birmingham

44195

Cleveland Clinic Foundation, Cleveland

48202

Henry Ford Hospital, Detroit

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

94143

UCSF Medical Center-Parnassus, San Francisco

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01849146 - Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter